Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
about
Human tumor antigens recognized by T lymphocytesT-cell clonotypes in cancerT cell avidity and tumor recognition: implications and therapeutic strategies.Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapyA practical approach to T-cell receptor cloning and expression.Gene therapy: development of immunostimulatory treatments for cancer.Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cellsSpecific roles of each TCR hemichain in generating functional chain-centric TCR.In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)Tumor antigens discovery: perspectives for cancer therapy.Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.CD8+ T cells specific for the islet autoantigen IGRP are restricted in their T cell receptor chain usage.Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.Generation and characterization of gp100 peptide-specific NK-T cell clones.T cell receptor (TCR) repertoire in alloimmune responses.Tumor recognition by the cellular immune system: new aspects of tumor immunology.Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients.A rare case of amelanotic malignant melanoma in the oral region: Clinical investigation and immunohistochemical study.T Cell Receptor Profiling in Type 1 Diabetes.Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.
P2860
Q24678508-192C77BD-A831-44E1-AD0B-5DB063C4DAD2Q24803891-F940C6F3-E376-4E91-8330-B0EE78936995Q24815775-8D066299-D0D1-413C-9E6E-E6EBE7C955DFQ33911899-9641A85B-580A-4BCE-B04D-566721B1B7CAQ34088001-B9636941-2F9C-45DE-8617-E51DB5FF61A1Q34187915-0103C1E8-2B3C-4439-BA58-870AB7D8A98DQ34674715-11D5FA0B-A3DA-4115-BA97-019B26CF8370Q35205495-CFBBD292-DDD0-499F-90BC-DA04DAD4A359Q35996832-5D500C7B-E6F9-420A-AFC1-2A0E1127208EQ36327157-5F67374B-CC1A-4514-881E-311603C82D4DQ36365751-B553C481-506C-4663-8004-9EFECC1E82DFQ36367223-EACAC7F5-05CF-4E08-8036-DDD25C90CF83Q36438078-99CA9C0C-B32E-4D8F-B699-117852920E5AQ37053497-63019191-B737-4D07-98D4-552F0EC67F5AQ37562613-2FDF78C3-1AB3-4465-9D04-779E969C90AAQ37704429-D98A6386-CDD8-4416-86B5-492CBC6EDAF6Q39767619-8F75C361-4716-4732-A5EF-2BAE77032F5AQ39778695-C89EACB9-D3B8-428D-837E-8BDAD5031C2EQ41060717-0F8316DA-9FB7-403A-A39F-C3E15B8AC4C0Q41091894-A3654E95-5227-4039-A38E-C549CE481766Q41455911-5466FFDD-F370-4A77-ADDA-B3C12CDD10F0Q41455932-84E94DA7-1BEA-43F3-9795-26A45B8C73EDQ41871262-9C31C2C4-9587-4B21-B184-0647E806178EQ41984654-2E682653-743A-4142-A226-BD5E70A2DFACQ42374922-E73CF392-55AF-408C-B7AE-395E8F79C234Q42615546-FD60D9EC-9E54-46AB-AD78-356B3A76FBC3Q43147458-27A3CB62-9AF0-475F-B4EF-B0E1322890AAQ55476901-3E4E96A0-D1D4-4989-8C16-F8787FECA19B
P2860
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@ast
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@en
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@nl
type
label
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@ast
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@en
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@nl
prefLabel
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@ast
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@en
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@nl
P2093
P2860
P356
P1476
Cytotoxic T-lymphocyte clones ...... lanoma antigen Melan-A/MART-1.
@en
P2093
Maccalli C
Mortarini R
Nicolini G
Radrizzani M
Rivoltini L
Traversari C
P2860
P304
P356
10.1073/PNAS.92.12.5674
P407
P577
1995-06-01T00:00:00Z